Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long‐term tenofovir or entecavir

Summary Background Suppression of hepatitis B virus (HBV) replication with nucelos(t)ide analogues should be considered for patients with chronic hepatitis D virus (HDV) infection and ongoing HBV replication. Aim To verify the clinical outcome after long‐term entecavir or tenofovir treatment in pati...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2019-04, Vol.49 (8), p.1071-1076
Main Authors: Brancaccio, Giuseppina, Fasano, Massimo, Grossi, Adriano, Santantonio, Teresa Antonia, Gaeta, Giovanni B.
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Bilirubin
Carcinoma, Hepatocellular - epidemiology
Chronic infection
Cirrhosis
Clinical outcomes
Deoxyribonucleic acid
DNA
Female
Fibrosis
Follow-Up Studies
Guanine - administration & dosage
Guanine - analogs & derivatives
Health risks
Hepatitis
Hepatitis B
Hepatitis B - drug therapy
Hepatitis B virus - drug effects
Hepatitis D, Chronic - drug therapy
Hepatocellular carcinoma
Humans
Infections
Interferon
Liver
Liver cirrhosis
Liver Cirrhosis - drug therapy
Liver diseases
Liver Neoplasms - epidemiology
Liver transplantation
Liver Transplantation - statistics & numerical data
Male
Middle Aged
Patients
Platelets
Prospective Studies
Replication
Tenofovir
Tenofovir - therapeutic use
Treatment Outcome
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Suppression of hepatitis B virus (HBV) replication with nucelos(t)ide analogues should be considered for patients with chronic hepatitis D virus (HDV) infection and ongoing HBV replication. Aim To verify the clinical outcome after long‐term entecavir or tenofovir treatment in patients with advanced fibrosis/cirrhosis, ineligible to peg‐interferon therapy. Methods Patients were prospectively followed‐up at 3‐6 month intervals; measured outcomes were decompensation, hepatocellular carcinoma (HCC), liver transplant and liver related death. HBV monoinfected patients receiving the same treatment served as reference after 1:1 matching by age, gender, platelet count, albumin level, bilirubin and INR. Results 56 HDV patients (48 with cirrhosis; median follow‐up 50 months) were enrolled; all achieved HBV DNA suppression. Death or liver transplant occurred in 19 patients, with a rate (n/1000 patient‐months) of 2.92 in HDV patients vs 0.38 in HBV monoinfected patients (P 
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.15188